HMNC Brain Health Reaches Key Milestone with Successful Patient Randomization in Phase 2b OLIVE Trial for Major Depressive Disorder

HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering personalized treatments powered by predictive co...

January 14, 2025 | Tuesday | News
Pfizer Announces Positive Phase 3 CREST Trial Results for Sasanlimab in High-Risk Non-Muscle Invasive Bladder Cancer

Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1...

January 13, 2025 | Monday | News
Vertex Pharmaceuticals and Zai Lab Announce Exclusive Collaboration for Development and Commercialization of Povetacicept in Asia

-Vertex Pharmaceuticals Incorporated  and Zai Lab Limited announced an exclusive collaboration and license agreement for the development a...

January 13, 2025 | Monday | News
Andreessen Horowitz (a16z) and Eli Lilly Launch $500 Million Biotech Ecosystem Venture Fund to Drive Healthcare Innovation

Andreessen Horowitz (a16z) Bio + Health  announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health...

January 13, 2025 | Monday | News
Gilead Sciences and LEO Pharma Form Strategic Partnership to Advance STAT6 Oral Therapies for Inflammatory Diseases

-Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma  announced a strategic partnership to accelerate the development and commercializatio...

January 13, 2025 | Monday | News
Japan-Based Meiji Seika Pharma Invests $20 Million in U.S.-Based MPM BioImpact to Drive Innovations in Virology and Biotech

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announce...

January 13, 2025 | Monday | News
NextCure Doses First Patient in Phase 1 Study of LNCB74, a Promising Cancer Therapy

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-c...

January 13, 2025 | Monday | News
etherna Immunotherapies and Dropshot Therapeutics Join Forces to Accelerate RNA-Based Therapeutics Development

etherna immunotherapies NV (“etherna”), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announc...

January 10, 2025 | Friday | News
InkSpace Imaging Receives FDA Clearance for Next-Generation 1.5T 24-Channel MR Coil

InkSpace Imaging, a leader in MRI coil innovation, announced that the United States (US) Food and Drug Administration (FDA) has cleared InkSpace Imaging&rs...

January 09, 2025 | Thursday | News
HUTCHMED and AstraZeneca's ORPATHYS® + TAGRISSO® Combo for MET-Driven NSCLC Granted Priority Review by China’s NMPA

HUTCHMED (China) announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO&re...

January 02, 2025 | Thursday | News
Corcept Therapeutics Submits NDA to FDA for Relacorilant to Treat Cushing’s Syndrome

Corcept Therapeutics, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab...

January 02, 2025 | Thursday | News
Viracta Therapeutics Initiates Strategic Review and Halts NAVAL-1 Trial to Conserve Resources

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancer...

December 27, 2024 | Friday | News
Hoth Therapeutics Secures Exclusive Patent License from VA and Emory University to Tackle Obesity and Related Diseases

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...

December 27, 2024 | Friday | News
Fujirebio and Eisai Forge Partnership to Advance Blood-Based Diagnostics for Neurodegenerative Diseases

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Cha...

December 26, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close